로딩 중…
지수 로딩 중…
HLB PHARMACEUTICAL CO., LTD.
047920· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,270-4.13%
2026-09-18
Financials
Valuation Metrics
HLB PHARMACEUTICAL CO., LTD.'s Market Cap is ₩2057B. At end of 2025 it was ₩4848B. Ranked #841 of 2,421 in KR market (top 35%), #389 of 1,640 on KOSDAQ (top 24%), #88 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 205.65B KRW | KR#841/2,421 Sec#88/231 |
| Revenue | 251.95B KRW | KR#913/2,421 Sec#48/231 |
| Net Income | 2.76B KRW | KR#1,363/2,421 Sec#96/231 |
| Total Assets | 178.03B KRW | KR#1,389/2,421 Sec#103/231 |
| Net Assets | 130.76B KRW | KR#1,227/2,421 Sec#94/231 |
| Employees | 207 | KR#1,073/2,421 Sec#90/231 |
| Value | ||
| P/E | 74.59x | KR#1,460/2,421 Sec#96/231 |
| P/B | 1.57x | KR#1,801/2,421 Sec#128/231 |
| P/S | 0.82x | KR#1,253/2,421 Sec#70/231 |
| EV/EBITDA | 115.56x | KR#1,505/2,421 Sec#100/231 |
| FCF Yield | -3.23% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 2.11% | KR#1,397/2,421 Sec#95/231 |
| ROA | 1.55% | KR#1,302/2,421 Sec#93/231 |
| Op. Margin | 0.74% | KR#1,529/2,421 Sec#107/231 |
| Revenue Growth | 68.61% | KR#140/2,421 Sec#22/231 |
| Earnings Growth | -50.86% | KR#1,058/2,421 Sec#71/231 |
| Financial Health | ||
| Debt Ratio | 36.15% | KR#713/2,421 Sec#87/231 |
| Total Debt | 15.00B KRW | KR#1,495/2,421 Sec#127/231 |
| FCF | -6.64B KRW | KR#1,575/2,421 Sec#126/231 |
| Cash | 4.51B KRW | KR#2,040/2,421 Sec#190/231 |
| Current Ratio | 1.88x | KR#927/2,421 Sec#104/231 |
| Net Debt/EBITDA | 5.61x | KR#1,066/2,421 Sec#78/231 |
| Performance | ||
| 1Y Return | -53.17% | KR#2,116/2,421 Sec#196/231 |
| 1M Return | -25.62% | KR#2,339/2,421 Sec#217/231 |
| From 52W High | -69.42% | KR#2,179/2,421 Sec#187/231 |
| 1Y MDD | -70.48% | KR#2,012/2,421 Sec#176/231 |
| Trading | ||
| Volume | 125,679 shares | KR#679/2,421 Sec#60/231 |
| Trading Value | 799.6M KRW | KR#782/2,421 Sec#78/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | 84 KRW | KR#1,450/2,421 Sec#98/231 |
| BPS | 3,987 KRW | KR#1,675/2,421 Sec#122/231 |
Company Info
동사는 1998년 씨트리로 설립되어 2020년 HLB그룹 편입과 함께 현 사명으로 변경함. 주요 사업은 전문의약품 제조·판매, 위수탁(CMO) 사업, 건강기능식품 판매이며, 로수듀오 등 160종 이상의 전문의약품을 위탁영업으로 판매하고 있음. 동탄 연구소 중심으로 주사제형 기반 신약 연구개발, 향남 신공장 신축으로 GMP 고도화, 시험 투자 확대로 경쟁력을 강화하고 있음. HLB제약는 1998년에 설립되었으며 경기도 남양주시에 본사를 두고 있습니다.